Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/8/2017
SIETES contiene 91969 citas

 
 
 1 a 20 de 795 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
2. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
3. Cita con resumen
Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, Lassila R, Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf 2017;26:657-65. [Ref.ID 101963]
4. Cita con resumen
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52. [Ref.ID 101934]
5. Cita con resumen
Anónimo. Anticoagulation for elderly patients at high risk for falls with atrial fibrillation. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:35-6. [Ref.ID 101488]
6.Enlace a cita original Cita con resumen
Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, Solà I, Pequeño Saco S, Alsonso Coello P. Patients ’ and physicians ’ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Family Practice 2017;18:1-11. [Ref.ID 101484]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101480]
8. Cita con resumen
Guillón A, Suárez C, Díez-Manglano J, Formiga F, Cepeda JM, Pose A, Camafort M, Castiella J, Rovira E, Mostaza JM. Características y tratamiento antitrombótico de los pacientes ancianos con fibrilación auricular no valvular hospitalizados en Medicina Interna. Registro NONAVASC. Med Clin (Barc) 2017;148:204-10. [Ref.ID 101448]
10.Enlace a cita original Cita con resumen
Wändell P, Carlsson AX, Holzmann M, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation - A cohort study in primary care. Eur J Clin Pharmacol 2017;73:febrero. [Ref.ID 101404]
11. Cita con resumen
Anónimo. Mirabégron: fibrillations auriculaires. Prescrire 2017;37:25. [Ref.ID 101365]
12. Cita con resumen
Anónimo. Décongestionnants rhinopharyngés: fibrillations auriculaires. Prescrire 2017;37:24. [Ref.ID 101364]
13.Tiene citas relacionadas
Jolly SS, Natarajan MK. Atrial fibrillation and PCI - Do we still need aspirin?. N Engl J Med 2016;373:2490-2. [Ref.ID 101034]
14.Tiene citas relacionadas Cita con resumen
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;373:2423-34. [Ref.ID 101032]
15. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA 2016;176:1662-71. [Ref.ID 100958]
16.Enlace a cita original Cita con resumen
Antoniou T, Macdonald EM, Hollands S, Gomes T, Tadrous M, Mamdani M, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. Can Med Assoc J 2016:21 de noviembre. [Ref.ID 100954]
17. Cita con resumen
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH, ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. [Ref.ID 100910]
18.Enlace a cita original Cita con resumen
Mahtani KR, Heneghan C. Novel oral anticoagulants for atrial fibrillation. BMJ 2016;354:i5187. [Ref.ID 100782]
19. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016:3 de octubre. [Ref.ID 100779]
20.Tiene citas relacionadas Cita con resumen
Larsen TB, Nielsen PB. Stroke and mortality after atrial fibrillation—a global struggle. Lancet 2016;388:1131-2. [Ref.ID 100749]
Seleccionar todas
 
 1 a 20 de 795 siguiente >>